Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: Pre-Exposure Prophylaxis of HIV Infection

In brief

The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV-1 infection. The primary objective of this study is to evaluate the efficacy of LEN for HIV-1 PrEP in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth at risk of HIV-1 infection.

Key facts

Study ID
NCT04925752
Run by
Gilead Sciences
People needed
3292
Starts
2021-06-28
Expected to finish
2028-08-01
Last updated by the study team
2025-12-23

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.